Compare PubMatic Inc (PUBM) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Tempus AI — how do they compare? PubMatic Inc trades at $18.56 (market cap $850.88M), while Tempus AI trades at $70.3 (market cap $12.58B). The key difference: Tempus AI is far larger — about 14.8× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Tempus AI for 22 Days on average.
| PUBM | TEM | |
|---|---|---|
Market Cap | $850.88M | $12.58B |
Volume | 997,698 | 7,444,569 |
Sector | Technology | Broad Market / Factor |
52-Week High | $19.18 | $99.28 |
52-Week Low | $6.28 | $41.55 |
Typical Hold Time | 40 Days | 22 Days |
Enterprise Value | $754.01M | $13.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic trades at $18.57, up 1.2% with a bullish technical signal. The stock shows strong analyst support with 11 buy ratings and a $19.89 consensus target. Recent Q2 2026 earnings beat expectations with $0.12 EPS versus $0.03 estimate, while revenue grew 10.5% year-over-year. The company maintains robust operating cash flow of $81M in 2025 and has strengthened its leadership with new executive appointments.
Despite negative net margins, PubMatic demonstrates operational strength through consistent cash generation and revenue growth. The primary investment opportunity lies in AI-driven ad tech expansion and market share gains, while risks include competitive pressures and profitability challenges. The stock appears fairly valued with potential upside to analyst targets.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
